KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Recursion Pharmaceuticals (RXRX) EBIT (2020 - 2025)

Historic EBIT for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Q3 2025 value amounting to -$172.2 million.

  • Recursion Pharmaceuticals' EBIT fell 7508.39% to -$172.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$723.6 million, marking a year-over-year decrease of 8356.81%. This contributed to the annual value of -$479.0 million for FY2024, which is 3683.48% down from last year.
  • As of Q3 2025, Recursion Pharmaceuticals' EBIT stood at -$172.2 million, which was down 7508.39% from -$176.2 million recorded in Q2 2025.
  • In the past 5 years, Recursion Pharmaceuticals' EBIT ranged from a high of -$30.5 million in Q1 2021 and a low of -$191.4 million during Q1 2025
  • For the 5-year period, Recursion Pharmaceuticals' EBIT averaged around -$94.6 million, with its median value being -$81.7 million (2023).
  • As far as peak fluctuations go, Recursion Pharmaceuticals' EBIT crashed by 15393.85% in 2021, and later soared by 612.38% in 2022.
  • Recursion Pharmaceuticals' EBIT (Quarter) stood at -$65.0 million in 2021, then rose by 6.12% to -$61.0 million in 2022, then tumbled by 62.23% to -$98.9 million in 2023, then plummeted by 85.76% to -$183.8 million in 2024, then rose by 6.29% to -$172.2 million in 2025.
  • Its EBIT stands at -$172.2 million for Q3 2025, versus -$176.2 million for Q2 2025 and -$191.4 million for Q1 2025.